Baxter price target lowered to $17 from $19 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Baxter (BAX) to $17 from $19 and keeps a Neutral rating on the shares. Baxter’s Q1 results reflected ongoing operational and margin headwinds with declining sales and sharply lower EPS, but still modestly exceeded expectations and reaffirmed full-year guidance, helping stabilize sentiment after significant underperformance and potentially re-engaging interest despite a still-challenging outlook, the analyst tells investors in a research note.